A randomized controlled study of indobufen and aspirin in the prevention of 1-year restenosis after off-pump coronary artery bypass

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100051267

Enrollment

Unknown

Registered

2021-09-17

Start date

2016-12-01

Completion date

Unknown

Last updated

2022-08-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary heart disease

Interventions

aspirin group:aspirin +clopidogrel

indobufen group:indobufen +clopidogrel

Eligibility

Sex/Gender

All

Age

40 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed with coronary heart disease and undergoing coronary artery bypass grafting; 2. Great saphenous vein and internal mammary artery were used as graft vessels; 3. Those who have no history of allergy to the drugs involved in this study; 4. Aspirin was stopped 5 ~ 7 days before operation.

Exclusion criteria

Exclusion criteria: 1. Patients with severe organic diseases of other systems; 2. Those with coagulation dysfunction or bleeding tendency; 3. Patients with malignant tumors; 4. Those who have recently undergone other types of heart surgery.

Design outcomes

Primary

Measure	Time frame
Graft patency;	—

Secondary

Measure	Time frame
major adverse cardiac event;	—

Countries

China

Contacts

Public ContactChen Bai

Capital Medical University affiliated Beijing Anzhen Hospital

vampire-113@163.com+86 15810200113

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026